Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Using DNA-encoded Libraries of Fragments for Hit Discovery of Challenging Therapeutic Targets

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Future challenges with DNA-encoded chemical libraries in the drug discovery domain.

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Protein-templated Ligand Discovery Via the Selection of DNA-encoded Dynamic Libraries

Strategies for developing DNA-encoded libraries beyond binding assays

Recent advances in DNA-encoded dynamic libraries

Abstract 3091: Discovery of highly selective ligands with unique binding modes for challenging oncology targets using DNA-encoded chemical libraries

Small-molecule discovery through DNA-encoded libraries

Application of Fragment-Based Drug Discovery to Versatile Targets

Evolutions in Fragment-Based Drug Design: the Deconstruction-Reconstruction Approach.

Challenges and Prospects of DNA-Encoded Library Data Interpretation

ABPP-CoDEL: Activity-Based Proteome Profiling-Guided Discovery of Tyrosine-Targeting Covalent Inhibitors from DNA-Encoded Libraries

Fragment Informatics and Computational Fragment‐Based Drug Design: an Overview and Update

Discovering Cell-targeting Ligands and the Cell Surface Receptors via Selection of DNA-encoded Chemical Libraries (DELs) against Cancer Cells without Predefined Targets

Machine learning on DNA-encoded libraries: A new paradigm for hit-finding

Evaluating the Diversity and Target Addressability of DNA-encoded Libraries using BM-Scaffold Analysis and Machine Learning

Quantitative Validation and Application of the Photo-Cross-Linking Selection for Double-Stranded DNA-Encoded Libraries

Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity

Compound Libraries: Recent Advances and Their Applications in Drug Discovery.